---
layout: default
title: Diclofenac
parent: Model Prediction Only (L5)
nav_order: 277
evidence_level: L5
indication_count: 10
---

# Diclofenac
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Diclofenac: From NSAID Use to Hypotrichosis Simplex of the Scalp

## One-Sentence Summary

Diclofenac is a marketed nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX).
The TxGNN model predicts it may be effective for **hypotrichosis simplex of the scalp**, a hereditary hair-loss disorder.
**No clinical trials and no publications** currently support this prediction, so it rests on the model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 20 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not yet available from DrugBank. Diclofenac is known as a COX-1/COX-2 inhibitor that reduces prostaglandin-mediated inflammation and pain.

The predicted disease is different in kind. Hypotrichosis simplex of the scalp is a hereditary hair-follicle disorder. It is not driven by prostaglandin-mediated inflammation, so COX inhibition has no plausible link to its cause.

The high score most likely reflects the topology of the knowledge graph rather than biology. Nothing in the clinical or preclinical literature supports it, so this prediction should be treated as a statistical artifact until shown otherwise.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Five of the 20 authorizations are shown below.

| DIN | Product Name |
|---------|------|
| 02534525 | JAMP DICLOFENAC |
| 02158582 | TEVA-DICLOFENAC SR |
| 02381680 | CAMBIA |
| 02338580 | VOLTAREN EMULGEL JOINT PAIN REGULAR STRENGTH |
| 02261774 | SANDOZ DICLOFENAC RAPIDE |

---

## Safety Considerations

No drug interaction records were found for this drug in the queried source.

Please refer to the package insert for safety information. The Health Canada package insert warnings and contraindications have not yet been retrieved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no clinical, literature or mechanistic support, and the biology of a hereditary hair-follicle disorder does not fit COX inhibition. It stays at evidence level L5 (model prediction only).

**To proceed, the following is needed:**
- Any preclinical or clinical signal for diclofenac in hereditary hair disorders. None was found.
- Health Canada package insert warnings and contraindications.
- Mechanism of action data from DrugBank.

**Note on other predictions in this pack:** The only prediction with real supporting data is **juvenile idiopathic arthritis** (rank 9, L3, Research Question). It has older small studies of diclofenac in juvenile arthritis, including a 1988 crossover study against naproxen and tolmetin. However, NSAIDs are already a standard symptomatic therapy there, so this is closer to an existing class use than true repurposing. If the team wants a lead for further work, it should start there, ideally with a paediatric safety review first.

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

